Phase 2/3 Clinical Trial for Advanced/Metastatic/Unresectable #BiliaryTractCancer Builds on Promising Results of Earlier Study
#COMPANION002 #NCT05506943
#cholangiocarcinoma
physicianresources.roswellpark.org/news/phase-2/3…

The ILCA 2024 Single Topic Workshop just started with the inspiring opening remarks of our co-chairs Lorenza Rimassa and Tim Meyer. We are ready to delve into systemic therapy and hear what groundbreaking updates our colleagues will bring to the discussion. 💬

Stay tuned!
#STW24

Both #cholangiocarcinoma & #AMMF were mentioned in today’s Westminster debate, 'Health inequalities in liver disease and liver cancer', & our white paper Rethink Liver Cancer was part of the briefing pack! Thank you Alison Thewliss 🧡 & Navendu Mishra
#livertwitter #RethinkLiverCancer

Proudly representing the C3 with our matching C3 merch at the Canadian Canadian Cancer Society Breakthrough Team Grant review meeting in Vancouver!

Thank you Canadian Cancer Society and CIHR for funding the C3 - as well as the other BTG projects!

TRAIL-targeting therapies still hold promise in cholangiocarcinoma, according to new research from CMGH
ow.ly/1y3u50Rk7yH

Study compares minor vs. major hepatectomy in Bismuth II hilar cholangiocarcinoma. Minor shows benefits: less blood loss, shorter surgery time, quicker bowel recovery. Outcomes similar. #Hepatectomy #Cholangiocarcinoma #SurgicalOutcomes

#AMMF ’s European #Cholangiocarcinoma Conference is 08-10 May – don’t miss it! Hear from the world’s leading CCA experts including oncologist, Prof John Bridgewater and surgeon, Mr Hassan Malik. REGISTER NOW (virtual or in person): ammf.org.uk/ammf-conferenc…

#livertwitter

Prognostic value of microRNA-21 in intra- and extrahepatic cholangiocarcinoma after radical resection: cohort study
➡️doi.org/10.1093/bjsope…

In this cohort study of 131 patients with intrahepatic or extrahepatic cholangiocarcinoma, miR-21 expression was strongly and…

#AMMF ’s European #Cholangiocarcinoma Conference is coming soon – 08-10 May! Learn about the hidden role of pathology from Dr Tim Kendall, and Dr Isioma Egbuniwe’s report on her novel CCA research. REGISTER NOW (virtual or in person): ammf.org.uk/ammf-conferenc…

#bileductcancer

New in The Innovation Medicine! Igniting cold tumors of intrahepatic cholangiocarcinoma: An insight into immune evasion and tumor immune microenvironment.
In this review, we explore the mechanisms contributing to the cold phenotype of intrahepatic cholangiocarcinoma, shedding…

Novel nomogram for perihilar cholangiocarcinoma predicts lymph node metastasis with age, CA19-9 levels as factors. C-index 0.763 proves high accuracy in a 160 patient study. #CancerPrediction #Oncology #Cholangiocarcinoma #MedicalInnovation

Delighted to present 🖥️Shalamar Institute of Health Sciences
8th Surgical Symposium on molecular
profiling 🧬 for #cholangiocarcinoma

Many 🙏🏼 to Prof Talat Waseem FRCSEng, FACS for the invite
and hope to visit 🇵🇰 in person next time!

#mutationsmatter #precisiononcology
Cholangiocarcinoma Foundation ENS-CCA AMMF

Rebecca Auer, MD presents a message of hope for #biliary tract cancer patients as lead for a Breakthrough Team Grant review meeting Research at Canadian Cancer Society !!

Cholangiocarcinoma Foundation Global Cholangiocarcinoma Alliance

Delighted to share #cholangiocarcinoma great debate from Society of Surgical Oncology #SSO23 has been published in AnnalsSurgOncology.

Kudos 👏🏽 to the debaters, moderators and co-authors Hop S. Tran Cao Cristina Ferrone Shishir K. Maithel

Is it finally time for a randomized trial?
OHSU Department of Surgery OHSU Knight Cancer Institute

Join Yelena Y. Janjigian MD, Dr. Shubham Pant & Dr. Strickler as they discuss treatment plans with HER2-targeted therapies for #GImalignancies & where these options fit in current guideline recommendations. 5/31 at 6:30 PM CDT at #ASCO24 ! With @CureCC & Colorectal Cancer Alliance: bit.ly/2024GIT

Dr. Katie Kelley & Dr. Tim Greten from have been awarded the 2024 CCF Innovation Grant, funded by the Bachrach Family Foundation. Their project aims to understand resistance in cholangiocarcinoma, potentially improving treatment outcomes. Learn more: curecca.link/Innovation.

This study challenges the idea that cancer is caused only by permanent changes to DNA go.nature.com/3Wfy4fb

A closed-loop drug-delivery system could improve chemotherapy: New CLAUDIA system could continuously monitor patients during an infusion and adjust dosage to maintain optimal drug levels.
news.mit.edu/2024/closed-lo…

Durvalumab plus chemotherapy produced superior 3-year survival outcomes vs chemotherapy alone in advanced biliary tract cancer. Seoul National University Hospital @seoulnatluni #oncology onclive.com/view/durvaluma…

Highlighting importance of sequencing in biliary tract cancer and adequate biopsy sampling to enable molecular profiling, with future potential of liquid biopsy AMMF